Cordys Analytics
Cordys Analytics builds Galvo, an MDR-certified deep-learning platform that reads 12-lead ECGs and flags more than 38 cardiac conditions. Spun out of UMC Utrecht, it also runs an outsourced Holter analysis service for European clinics.
What is Cordys Analytics?
Cordys Analytics is a Dutch health-technology company that develops Galvo, an artificial-intelligence platform for reading electrocardiograms. It is a spin-out of University Medical Center Utrecht, and the research behind it began there in 2018, led by Rene van Es, an associate professor of cardiology, and Rutger van de Leur, a physician and PhD researcher. Their goal was to build deep-learning algorithms capable of detecting heart disease from 12-lead ECGs. UMC Utrecht supplied more than 1.5 million annotated recordings to train and validate the models, and the resulting tools outperformed the software already embedded in ECG machines. The company was created and funded as a spin-out in 2023, when John van den Berg joined as chief executive.
The platform reads 12-lead ECGs and identifies more than 38 cardiac conditions, among them arrhythmias, ischaemia and heart failure. Cordys presents it as clinical decision support meant to shorten diagnostic delays, reduce unnecessary follow-up testing and relieve pressure on stretched care teams, not as a substitute for a clinician's reading. The software is deliberately vendor-agnostic: it connects healthcare organisations and ECG devices from different manufacturers, covering everything from hospital 12-lead machines to wearables. A cloud architecture provides real-time analysis, remote access and scalability behind a proprietary interface.
Four audiences are named on the site: hospital cardiologists and other physicians, prehospital care through general practitioners and ambulance services, ECG-AI algorithms spanning rhythm disorders to heart failure, and ECG device fleets. In August 2025 the Galvo platform received MDR Class IIb certification and the company achieved ISO 13485, both confirmed by notified body TUV SUD. On 1 January 2026 Cordys extended into Holter analysis services, with in-house ECG analysts reviewing what the algorithm has produced, writing structured reports and escalating urgent findings; resting, stress and wearable ECG services are named as the next steps.
The company works from the UtrechtInc incubator in Utrecht and, since June 2026, from the Barcelona Health Hub. Its clinical evidence section lists eight peer-reviewed papers published between 2020 and 2026, and commercial pilots are planned in the Netherlands, Spain, Italy and France.
What it does
- Analyse 12-lead ECGs automatically using deep learning
- Detect more than 38 cardiac conditions, including arrhythmias, ischaemia and heart failure
- Triage incoming ECGs and surface urgent findings immediately
- Produce structured diagnostic reports for clinicians
- Process Holter recordings as an outsourced analysis service
- Connect to ECG hardware from different manufacturers, from 12-lead machines to wearables
- Run analysis in the cloud, in real time and accessible remotely
When to use Cordys Analytics / When not to
A quick filter to help you decide if Cordys Analytics is the right fit.
When to use Cordys Analytics
- Cardiologists and hospital cardiology departments handling high volumes of 12-lead ECGs
- General practitioners and ambulance services carrying out prehospital cardiac assessment
- Diagnostic centres that need Holter analysis without building an in-house reading team
- European healthcare providers required to buy MDR-certified, ISO 13485-covered medical devices
- Cardiology research groups looking for an AI-ECG platform with published peer-reviewed validation
When not to use Cordys Analytics
- Individuals wanting a consumer heart-monitoring app: there is no signup, no mobile app and no free tier
- Buyers who need a published price before agreeing to talk to a salesperson
- Procurement and data protection teams that require a privacy policy, terms and a DPA to be publicly available
- Developers hoping to self-serve an integration, since no API documentation is published
- Clinicians expecting an autonomous diagnosis rather than decision support with human review
How to use Cordys Analytics
A typical end-to-end flow, from setup to results.
- Read the Impact and Clinical Evidence sections of the site to see which cardiac conditions the algorithms cover and how they were validated
- Decide which of the two offerings applies: the Galvo software platform for 12-lead ECG analysis, or the outsourced Holter analysis service
- Email info@cordys.health to open a conversation, since there is no signup form, no free trial and no self-service checkout
- Discuss scope with the team, bearing in mind that deployments are described as commercial pilots rather than off-the-shelf installations
- Request the contractual and regulatory documents that are not published: privacy policy, terms, DPA, hosting location and the device Instructions for Use
- Agree how ECGs will reach the platform; the software is vendor-agnostic and is said to connect existing healthcare organisations and ECG devices
- For the Holter service, send recordings in and receive structured reports back, with an ECG analyst reviewing what the algorithm produced
- Use the returned analysis as clinical decision support alongside, and never instead of, clinician interpretation
- Contact support@cordys.health for product support once the platform is running
- Visit the Utrecht or Barcelona office if an in-person meeting helps, as the company invites visitors to both
Pros & Cons
Pros
- Unusually strong evidence base: eight peer-reviewed papers listed, in journals including the European Heart Journal, Europace and Heart Rhythm
- MDR Class IIb and ISO 13485 certification from TUV SUD, obtained within a year of the company's formation
- Algorithms trained and validated on more than 1.5 million annotated ECGs supplied by UMC Utrecht
- Direct academic lineage: a UMC Utrecht spin-out with a long-term research agreement with the hospital
- Vendor-agnostic software that does not require replacing existing ECG hardware
- Documented human review in the Holter service, so the algorithm never reports alone
- Diversified and largely non-dilutive funding, from a 900,000 euro seed round to Eurostars, Health Holland and NWO support
Cons
- No published pricing, no free plan and no trial, so cost cannot be assessed without contacting the company
- No privacy policy, terms and conditions, legal notice or data processing agreement anywhere on the site
- Nothing published about data hosting location, retention, subprocessors or training on customer data
- No API documentation or developer page, so an integration cannot be scoped from public material
- Single-page site with no dedicated product page: Galvo is named only in team biographies and two blog posts
- No mobile app, no demo and no named customers beyond the Ksyos collaboration; deployments are pilots
- Young company with eleven named staff, which is a scale consideration for hospital procurement
Pricing & Plans
Cordys Analytics publishes no pricing. There is no price list, no permanent free plan and no free trial anywhere on the site, and a complete sitemap confirms that no pricing page exists. The commercial model is therefore contact-sales: the only purchase path shown is to email the company, both for the Galvo platform and for the Holter analysis service. Prospective buyers should note that the monetary figures appearing on the site, such as a 900,000 euro seed round, an 800,000 euro Eurostars grant and 650,000 euros from Health Holland and the EU, are funding amounts and not prices.
- price on request
- price on request
Data, GDPR & hosting
A consolidated view of how Cordys Analytics handles your data.
GDPR overview
There is no GDPR mention of any kind on this site. Cordys Analytics publishes no privacy policy, no terms and conditions, no legal notice, no data processing agreement and no trust or security page; a complete sitemap and a full-text search of every collected page confirm the absence rather than merely failing to find it. No data protection officer is named and no Article 27 representative is designated, which is consistent with a controller established inside the EU: the company operates from Utrecht in the Netherlands and from Barcelona in Spain. The certifications it does publish belong to a different regime altogether. MDR Class IIb and ISO 13485, granted by notified body TUV SUD in August 2025, govern medical device safety and quality management, not personal data protection. Anyone intending to process patient ECGs through this platform must request the GDPR documentation directly.
Who owns the data?
Cordys Analytics publishes no terms and conditions, no privacy policy and no legal notice, so the question of who owns the data processed by the platform is left unanswered in public. A complete sitemap of nineteen URLs and a full-text search of every page collected returned no ownership clause, no licence grant and no data processing agreement. What is documented is far narrower: the algorithms were trained and validated on more than 1.5 million annotated ECGs supplied by University Medical Center Utrecht. Ownership of the patient recordings sent in by clinics, hospitals and GP practices is addressed nowhere on the site, and would have to be settled contractually before any deployment.
Reuse rights
No public document sets out what a customer may do with the data or with the platform's output. With no terms and conditions and no privacy policy on the site, there is no reuse permission, no restriction and no licence to point to. The only training statement Cordys Analytics makes concerns its own historical dataset: more than 1.5 million annotated ECGs provided by UMC Utrecht, used to train and validate the algorithms. Nothing states whether customer recordings feed further model development, although the published ECG analyst job description does mention analysts giving feedback to improve the AI tools. Reuse terms must therefore be obtained directly from the company.
Data retention & training
Hosting summary
Cordys Analytics publishes no information about where data is hosted. There is no privacy policy, no terms and conditions and no trust or security page on the site, and no jurisdiction, country or region is named anywhere. The only architectural statement is that the platform is cloud-based, which the company presents as delivering real-time analysis, remote accessibility and scalability. That says nothing about location. The company itself is established in the Netherlands, with a second office in Spain, and its device carries MDR Class IIb certification issued by a European notified body, but none of that amounts to a hosting commitment. Any healthcare organisation subject to national rules on where patient data may reside will have to obtain the hosting jurisdiction, the subprocessor list and a data processing agreement directly from Cordys Analytics before contracting.
Things to keep in mind
Risks and trade-offs to weigh before adopting Cordys Analytics.
- No privacy policy, terms or data processing agreement is published, yet the platform processes patient ECGs, among the most sensitive categories of personal data
- Nothing is published about where data is hosted, how long it is kept, who the subprocessors are, or whether customer recordings feed model training
- Automation bias is a real clinical risk: a confident algorithmic reading can anchor a clinician's judgement, and manual ECG interpretation skills can erode if the tool is leaned on uncritically
- The platform is decision support rather than a diagnosis, so treating a clean algorithmic result as a definitive negative would misuse it
- Absent public pricing, total cost of ownership cannot be assessed before entering a sales conversation
- Deployments are described as pilots rather than large-scale production installations, so operational maturity deserves probing
- The device Instructions for Use sit behind a robots.txt exclusion, so the regulatory documentation cannot be reviewed before making contact
Setup & Integrations
Technical difficulty
Setup is not self-service. There is no account to create and nothing to download, and every engagement starts with an email to the company. For the Holter analysis service the client-side effort is light: recordings are sent in and structured reports come back. The Galvo platform is a different matter. It is cloud software described as vendor-agnostic and as connecting existing healthcare organisations and ECG devices, but no API documentation or integration guide is published, so interfacing it with hospital systems cannot be scoped in advance and must be planned with the vendor.
Deployment
Behind Cordys Analytics
Fundraising
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What does Cordys Analytics actually do?
Is it a certified medical device?
How much does it cost?
Does the AI make the diagnosis on its own?
Will it work with our existing ECG equipment?
What does the privacy policy say about patient data?
What data were the algorithms trained on?
Is there evidence that it works?
Is there an API or a mobile app?
Where is the company based?
Should you pick Cordys Analytics?
Cordys Analytics is one of the more credible AI-in-cardiology propositions on the market, and the reason is evidence rather than marketing. Eight peer-reviewed papers are listed on the site, published between 2020 and 2026 in journals including the European Heart Journal, Europace and Heart Rhythm. The algorithms were trained on more than 1.5 million annotated ECGs from UMC Utrecht, the hospital the company spun out of. The Galvo platform carries MDR Class IIb certification and the company holds ISO 13485, both signed off by TUV SUD, a demanding milestone reached within a year of incorporation.
Against that stands a striking documentary silence. The website publishes no pricing, no privacy policy, no terms and conditions, no legal notice, no data processing agreement and no statement of where data is hosted or how long it is kept. For a company whose product processes patient ECGs, that is the single most important thing a buyer should raise. A complete sitemap confirms these documents are genuinely absent rather than merely hard to find.
The company is also young and small: a 2023 spin-out with eleven named staff, moving from research into commercial pilots in the Netherlands, Spain, Italy and France, with a Holter analysis service launched in January 2026 and a Barcelona office added in June 2026. Deployments are described as pilots, not large-scale production installations.
For a cardiology department, a diagnostic centre or an ambulance service in Europe, Cordys is worth a conversation, particularly where existing ECG hardware has to stay in place, since the software is vendor-agnostic. Begin by requesting the contractual and hosting documentation the site does not publish, and treat the platform as decision support that supplements, never replaces, clinical interpretation.
- Choosing a selection results in a full page refresh.
- Opens in a new window.